The fact that the overweight, obese and morbidly obese population remains vastly undertreated (in the U.S. and worldwide) bodes very well for next-generation obesity drugs and devices, as it leaves significant room for companies to profit and grow revenues in the coming decade in a virtually untapped U.S. market, expected to be valued at more than $1.8 billion by the year 2020.
This dynamic, new report from Medtech Insight includes analyses of selected products, current/forecast markets, surgical procedure volumes, competitors, market share by supplier, and opportunities in the U.S. Obesity Drugs and Devices Market. Specifically, this report covers leading and emerging prescription-based weight loss (obesity) drugs, and minimally invasive medical devices, including: laparoscopic adjustable gastric banding (LAGB) systems, intragastric balloon systems, implantable gastric stimulation devices, and other emerging device-based technologies, including nonsurgical/incisionless, transorally inserted or next-generation minimally invasive weight loss device therapies.
In 2014, the total, combined U.S. market for "new" obesity drugs and (minimally invasive medical) devices for the treatment of obesity was estimated at approximately $374.7 million. Over the forecast period, the total market is expected to advance at a healthy, double-digit compound annual rate of 32.4%, from an estimated $455.4 million in 2015 to an estimated $1,852.1 million in the year 2020.
EXECUTIVE SUMMARY I. U.S. Obesity Drugs & Devices Market II. Methodology Exhibit ES-1: U.S. Obesity Drugs & Devices Market, 2013-2020 1. OBESITY DRUGS 1.1 Leading Obesity Drugs 1.1.1 Genentech/Roche Group (Xenical) 1.1.2 Vivus (Qsymia) 1.1.3 Arena Pharmaceuticals/Eisai (Belviq) 1.1.4 Orexigen Therapeutics/Takeda (Contrave) 1.2 Emerging Obesity Drugs 1.2.1 Gelesis (Gelesis100) 1.2.2 Hanmi Pharmaceuticals (LAPS CA-Exendin-4/HPP4404) 1.2.3 Novo Nordisk (Saxenda) 184.108.40.206 Victoza (liraglutide) 1.2.4 Orexigen Therapeutics (Empatic) 1.2.5 Rhythm Pharmaceuticals (RM-493) 1.2.6 Zafgen (Beloranib) 1.3 Market Analysis 1.3.1 Market Forecast 220.127.116.11 Market Drivers 18.104.22.168 Market Limiters 1.3.2 Competitive Analysis Exhibit 1-1: 2015, FDA Approved Obesity Drugs Exhibit 1-2: Xenical, SWOT Analysis Exhibit 1-3: Qsymia, SWOT Analysis Exhibit 1-4: Belviq, SWOT Analysis Exhibit 1-5: Contrave, SWOT Analysis Exhibit 1-6: 2015, Selected Obesity Drugs Recently FDA Approved or Under Development Exhibit 1-7: Gelesis100 Mechanism of Action Exhibit 1-8: New Obesity Drugs, Market Forecast, 2013-2020 Exhibit 1-9: 2013, New Obesity Drugs Market, Share by Supplier Exhibit 1-10: 2014, New Obesity Drugs Market, Share by Supplier 2. LAPAROSCOPIC ADJUSTABLE GASTRIC BANDING SYSTEMS 2.1 Leading LAGB Systems 2.1.1 Apollo Endosurgery 2.1.2 Ethicon Endo-Surgery/Johnson & Johnson 2.1.3 Other LAGB Systems (Available Outside the U.S.) 22.214.171.124 Agency for Medical Innovations 126.96.36.199 Cousin Biotech 188.8.131.52 Helioscopie 184.108.40.206 Medical Innovation Developpement 2.2 Market Analysis 2.2.1 Procedure Volumes Forecast 2.2.2 Market Forecast 220.127.116.11 Market Drivers 18.104.22.168 Market Limiters 2.2.3 Competitive Analysis Exhibit 2-1: Risks Associated with Gastric Banding and Abdominal/Bariatric Surgery Exhibit 2-2: 2015, Laparoscopic Adjustable Gastric Banding Systems Exhibit 2-3: Apollo EndoSurgery's LAP-BAND Exhibit 2-4: Key Benefits and Risks of the LAP-BAND Procedure Exhibit 2-5: Excess Weight Loss with the LAP-BAND System Compared to Roux-en-Y Gastric Bypass at 3 Years and Beyond Exhibit 2-6: Ethicon Endo-Surgery's Curved Adjustable Gastric Endo Band, Features and Benefits Exhibit 2-7: Comparison of Gastric Banding, Gastric Bypass, and Sleeve Gastrectomy Exhibit 2-8: Agency for Medical Innovations' Soft Gastric Band Premium Exhibit 2-9: Cousin Biotech's Bioring Adjustable Gastric Band Exhibit 2-10: Helioscopie's Heliogast HAGA Adjustable Gastric Band Exhibit 2-11: Medical Innovation Developpement's MIDBAND Adjustable Gastric Band Exhibit 2-12: Laparoscopic Adjustable Gastric Banding, Procedure Volumes Forecast, 2013-2020 Exhibit 2-13: Estimated Number of Bariatric Surgeries, U.S. Procedure Volumes Forecast, 2013-2020 Exhibit 2-14: 2015 and 2020, Comparison of Estimated Bariatric Surgical Volumes, by Percentage and Type of Surgery Exhibit 2-15: Laparoscopic Adjustable Gastric Banding, Market Forecast, 2013-2020 Exhibit 2-16: 2013, Laparoscopic Adjustable Gastric Banding Systems, Share by Supplier Exhibit 2-17: 2014, Laparoscopic Adjustable Gastric Banding Systems Market, Share by Supplier 3. INTRAGASTRIC BALLOON SYSTEMS 3.1 Apollo Endosurgery 3.2 Helioscopie 3.3 ReShape Medical 3.4 Spatz FGIA 3.5 Obalon Therapeutics 3.6 Market Analysis 3.6.1 Market Drivers 3.6.2 Market Limiters Exhibit 3-1: Apollo Endosurgery's Orbera Managed Weight Loss System Exhibit 3-2: Helioscopie's Heliosphere Intragastric Balloon Exhibit 3-3: ReShape Duo Intragastric Balloon System Exhibit 3-4: REDUCE Pivotal Trial Results Exhibit 3-5: The Spatz Adjustable Balloon System Exhibit 3-6: Risks of Intragastric Balloon Placement Exhibit 3-7: The Spatz Adjustable Balloon Procedure Exhibit 3-8: The Obalon Gastric Balloon System Features and Possible Complications Exhibit 3-9: Intragastric Balloon Therapy, Procedure Volumes Forecast, 2015-2020 Exhibit 3-10: Intragastric Balloon Systems, Market Forecast, 2015-2020 4. IMPLANTABLE VAGAL BLOCKING THERAPY 4.1 EnteroMedics 4.2 MetaCure 4.3 Market Analysis 4.3.1 Market Drivers 4.3.2 Market Limiters Exhibit 4-1: 2015, Implantable Pulse Generators Developed for the of Obesity Exhibit 4-2: EnteroMedics' Maestro System Exhibit 4-3: Overview of EnteroMedics' VBLOC Therapy and Vagus Nerve Function Exhibit 4-4: Potential Benefits and Risks of VBLOC Therapy Exhibit 4-5: Comparison of VBLOC Therapy, Laparoscopic Banding, and Gastric Bypass Exhibit 4-6: MetaCure's DIAMOND (TANTALUS) Gastric Stimulation System Exhibit 4-7: Implantable VBLOC Therapy Devices, EnteroMedics, Procedure Volumes Forecast, 2015-2020 Exhibit 4-8: Implantable VBLOC Therapy Devices, EnteroMedics, Market Forecast, 2015-2020 5. OTHER EMERGING MEDICAL DEVICE TECHNOLOGIES 5.1 Aspire Bariatrics 5.2 BAROnova 5.3 EndoSphere, Inc. 5.4 GI Dynamics 5.5 Onciomed 5.6 Scientific Intake 5.7 TransEnterix 5.8 USGI Medical 5.9 Others Exhibit 5-1: 2015, Selected Emerging Medical Device Technologies for the Treatment of Obesity Exhibit 5-2: Aspire Bariatric's AspireAssist Exhibit 5-3: EndoSphere's SatiSphere Exhibit 5-4: GI Dynamic's EndoBarrier Gastrointestinal Liner and Procedure Exhibit 5-5: Scientific Intake's SMART Device Exhibit 5-6: USGI Medical's Incisionless Operating Platform Exhibit 5-7: Primary Obesity Surgery, Endolumenal 6. TOTAL U.S. OBESITY DRUGS AND DEVICES MARKET ii. New Obesity Drugs Market iii. Obesity Devices Market Exhibit 6-1: U.S. Obesity Drugs & Devices Market, 2013-2020 Exhibit 6-2: U.S. New Obesity Drugs Market, 2013-2020 Exhibit 6-3: U.S. Obesity Devices Market, 2013-2020 APPENDIX: COMPANY LISTING